ArticleSAGE open medicine2026
Homocysteine as a biomarker in arthritis and depression: Evidence from NHANES and gene expression studies.
Article in SAGE open medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Rheumatoid arthritis (RA) and major depressive disorder (MDD) are interconnected conditions with a growing incidence, yet the mechanism that links them remains uncertain. This research focused on identifying the overlapping genes and pathogenic processes of RA and MDD via bioinformatics and National Health and Nutrition Examination Survey (NHANES) validation. Methods: The Gene Expression Omnibus (GEO) database provided RA and MDD-related data from datasets GSE715573 and GSE76826. To identify common differentially expressed genes (co-DEGs) between RA and MDD, a differential analysis was carried out with |logFC| > 0.5 and Results: Differential gene expression analysis identified 142 downregulated and 102 upregulated genes in RA peripheral blood, 935 upregulated genes, and 409 downregulated genes in MDD peripheral blood. Ten common genes (VNN1, CKAP4, CLEC4D, F5, CBS, TNFRSF25, NELL2, RNASE2, TXN, and SRPK1) were identified, and abnormal biosynthesis and catabolism process of cysteine was found as a comorbid link between RA and MDD. Population-level NHANES analysis confirmed higher serum Hcy associated with more severe depression symptoms in arthritis patients. Conclusions: This investigation reveals the overlapping genetic signatures that explain the common manifestations and the association between RA and MDD. The two diseases share DEGs of CBS, VNN1, and TXN, which indicates that the abnormal metabolic pathway of homocysteine is a common pathogenic pathway in RA and MDD. NHANES proved an association between Hcy and depression in arthritis participants, indicating that Hcy may be an important biomarker for intervention to delay or ultimately prevent comorbidities, and highlights the importance of dietary interventions such as supplementing folate. The knowledge may help develop novel therapies and a potential strategy to prevent or delay the coexistence of depression and arthritis, especially RA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.